Surui Sheng

Surui Sheng


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2008 in Journal of Physics D: Applied Physics
Verified
Journal Article
Closed access
SSSurui Sheng
Surui Sheng
PWP Wang
P Wang
XZX Y Zhang
X Y Zhang
COC K Ong
C K Ong

20 November 2020 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
LZLili Zhao
Lili Zhao
WLWenxi Li
Wenxi Li
XLXu Luo
Xu Luo
SSSurui Sheng
Surui Sheng

2 May 2024 in Oral Diseases
Verified
Journal Article
Closed access
YZYang Zheng
Yang Zheng
SSSurui Sheng
Surui Sheng
YMYanni Ma
Yanni Ma
YCYinan Chen
Yinan Chen
RLRuixin Liu
Ruixin Liu
ZZZhiyuan Zhang
Zhiyuan Zhang

1 October 2021 in Oral Oncology
Verified
Journal Article
Closed access
CMChunyue Ma
Chunyue Ma
SSSurui Sheng
Surui Sheng
YSYi Shen
Yi Shen
WGWeijin Gao
Weijin Gao
THThorsen Haugen
Thorsen Haugen
SJSun Jian
Sun Jian

11 July 2022 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
CMChunyue Ma
Chunyue Ma
SSSurui Sheng
Surui Sheng
WGW. Gao
W. Gao
THT. Haugen
T. Haugen
YZY. Zhu
Y. Zhu
YSYi Shen
Yi Shen

12 May 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZHZirong Huo
Zirong Huo
SFShuiting Fu
Shuiting Fu
CMChunyue Ma
Chunyue Ma
SSSurui Sheng
Surui Sheng
Background: As opposed to observation of the neck, elective neck dissection has a survival benefit for cN0 oropharyngeal squamous cell carcinoma (OPSCC). However, there are limited date on level IV neck dissection in human papillomavirus (HPV)-negative OPSCC because most earlier studies did not stratify by P16 or HPV status. Thus, whether to exclude level IV from selective dissection (SND) of cN0 HPV-negative OPSCC remains controversial. Methods: In this single-center retrospective cohort study, disease-free survival (DFS) was estimated as the primary endpoint for 124 cN0 HPV-negative OPSCC patients who received SND of levels I-III (Group A) and I-IV (Group B). Overall survival (OS) and disease-specific survival (DSS) were considered secondary endpoints. Results: For the entire cohort, the 5-year DFS rates of Groups A and B were 55.0% and 60.1%, respectively. Five-year OS rates were 58.9% and 61.5%, and 5-year DSS rates were 74.0% and 64.8%, respectively. Group B did not show higher 5-year DFS, OS, or DSS than Group A. Conclusions: This retrospective cohort study validated that in cN0 HPV-negative OPSCC, SND including level IV does not have substantial benefits regarding DFS, OS or DSS.